Reaction

Retinopathy reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 3,687 reports · 73 co-occurring drugs

As of the last recalculation, Retinopathy appears in 3,687 FAERS reports alongside 73 co-occurring drug terms. The strongest observed disproportionality signal is ENCORAFENIB (PRR 26.5).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Encorafenib	46	26.5	26.7
Hydroxychloroquine	290	23.7	23.8
Insulin Human	157	23.2	23.3
Ribavirin	219	20.4	20.4
Vemurafenib	34	16.1	16.2
Insulin Lispro	329	14.7	14.7
Human Insulin	30	13.7	13.7
Cefuroxime	26	12.9	12.9
Peginterferon Alfa-2A	100	10.7	10.7
Insulin Degludec	42	10.2	10.2
Trametinib	42	9.9	9.9
Insulin Glulisine	17	9.5	9.5
Insulin Glargine-Yfgn	36	9.4	9.4
Insulin Glargine	367	9.2	9.2
Oral Semaglutide	113	8.9	8.9
Dabrafenib	33	8.9	8.9
Melphalan Hydrochloride	35	7.9	8.0
Meperidine Hydrochloride	12	7.4	7.4
Melphalan	29	7.2	7.3
Insulin Aspart	81	7.1	7.1
Insulin	65	6.7	6.7
Prednisolone Acetate	11	6.0	6.0
Ritonavir 100 Mg	15	5.7	5.7
Atropine	8	5.5	5.5
Hydroxychloroquine Sulfate	85	5.4	5.4
Darunavir	14	5.2	5.2
Efavirenz	10	5.1	5.1
Doxepin	9	5.0	5.0
Ganciclovir Sodium	9	4.8	4.8
Epoetin Alfa	10	4.8	4.8
Atazanavir	12	4.7	4.7
Ganciclovir	8	4.4	4.4
Ritonavir	22	4.3	4.3
Raloxifene Hydrochloride	11	4.3	4.3
Fosaprepitant Dimeglumine	10	4.1	4.1
Brinzolamide	6	3.9	3.9
Dulaglutide	60	3.9	3.9
Erythropoietin	14	3.9	3.9
Etoposide	47	3.6	3.6
Deferasirox	17	3.6	3.6
Triamcinolone Acetonide Ointment Usp, 0.05%	15	3.6	3.6
Gemcitabine	25	3.6	3.6
Quinapril Hydrochloride	5	3.6	3.6
Pioglitazone	27	3.5	3.5
Brimonidine Tartrate	11	3.5	3.5
Gemcitabine Hydrochloride	32	3.4	3.4
Timolol Maleate	6	3.4	3.4
Ranibizumab	16	3.4	3.4
Micafungin Sodium	5	3.3	3.3
Sitagliptin	42	3.3	3.3
Pitavastatin Calcium	6	3.3	3.3
Palivizumab	9	3.3	3.3
Timolol	7	3.3	3.3
Ipilimumab	24	3.2	3.2
Dolutegravir Sodium	5	3.1	3.1
Aprepitant	10	3.1	3.1
Cisplatin	41	3.0	3.0
Triamcinolone Acetonide	16	2.9	2.9
Pemetrexed Disodium	19	2.8	2.8
Ziprasidone Mesylate	7	2.8	2.8
Linezolid	14	2.7	2.7
Interferon Beta-1B	8	2.4	2.4
Aflibercept	13	2.4	2.4
Atezolizumab	16	2.3	2.3
Carboplatin	52	2.3	2.3
Sofosbuvir	8	2.3	2.3
Paclitaxel (Aibumin-Bound)	33	2.3	2.3
Exenatide	21	2.3	2.3
Liraglutide	19	2.2	2.2
Vigabatrin	5	1.9	1.9
Tirzepatide	50	1.8	1.8
Durvalumab	6	1.7	1.7
Voxelotor	4	1.0	1.0

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.